People make their way near a Walgreens pharmacy on March 09, 2023 in New York City.
Leonardo Munoz | Corbis News | Getty Images
Green graves on Friday it reported fiscal first-quarter earnings and revenue that were above expectations, as it closes stores and cuts other costs to steer itself out of a rough spot.
Here's what Walgreens said for the three months ended Nov. 30 compared to Wall Street expectations, based on a survey of analysts by LSEG:
- Earnings per share: 51 cents adjusted versus 37 cents expected
- Income: $39.46 billion vs $37.36 billion expected
Even after the big hits, Walgreens maintained its fiscal 2025 adjusted earnings guidance of $1.40 to $1.80 per share. The company did not include annual sales guidance in its release. In October, Walgreens said it expects revenue for the fiscal year of $147 billion to $151 billion.
The company's shares were up more than 20% in morning trading.
“We have begun the fiscal year by making progress on our financial and strategic priorities, despite a challenging environment for our consumer,” Walgreens CEO Tim Wentworth said during Friday's earnings call.
“Importantly, we began to make progress on the opportunities that we consider necessary for our long-term turnaround,” he said, adding that the “cornerstone” of that effort is stabilize its US retail pharmacy business.
Walgreens capped off a rocky year marked by pharmacy reimbursement pressuresmarter consumer spending at its stores and related challenges push into primary careamong other issues. The results will come among reports that the company is in talks to sell itself to the private equity firm Sycamore Partners.
In the first fiscal quarter, Walgreens posted sales of $39.46 billion, up 7.5% from the same period a year ago, as its three business segments grew.
The company reported a net loss of $265 million, or 31 cents per share, for the first fiscal quarter. It compares with a net loss of $67 million, or 8 cents per share, for the prior year.
Walgreens said the loss was largely driven by a higher operating loss, which reflects its multi-year plan to close underperforming stores. That includes 1,200 over the next three years, with 500 in fiscal 2025 alone.
Walgreens has about 8,500 retail pharmacy locations across the U.S., according to their website. The company plans to “significantly accelerate the pace of our store closings from the first quarter,” Wentworth said.
Excluding certain items, adjusted earnings were 51 cents per share for the quarter.
In addition to closing the stores, Wentworth said Walgreens is “modernizing how we forecast, allocate and schedule labor” in its stores. The company is launching a new check-in model in approximately 200 locations in January to improve the in-store experience for customers, patients and employees.
The changes will schedule workers based on store-specific demand patterns, while also accounting for team member availability and preferences, he said.
Wentworth noted, however, that turning around the consumer retail business has been “more challenging with the continued decline in consumer discretionary spending. Consumers are facing pressure from inflation and higher interest rates, and continue to exhibit value-seeking behavior, Wenworth said.
“We are advancing several elements of our sales strategy,” he said. “While we are seeing early green shoots, we still have a lot of work to do here.”
Growth across business units
Walgreens posted growth across all three of its business segments in the first fiscal quarter.
The US retail pharmacy sector generated $30.87 billion in sales, an increase of 6.6% from the same period last year. Analysts had expected sales of $29.21 billion, according to estimates compiled by StreetAccount.
That unit operates the company's drug stores, which sell prescription and over-the-counter medications as well as health and wellness, beauty, personal care, and food products.
Walgreens said that pharmacy sales for the quarter rose 10.4% and comparable pharmacy sales were up 12.7% compared to the prior year due to price inflation in brand name drugs, among other factors.
Total prescriptions filled in the quarter, including vaccines, came to 316.3 million, a 1.5% increase from the same period a year ago. Retail sales fell 6.2% from the prior-year quarter, and comparable retail sales declined 4.6%. The company cited a weaker cough, cold and flu season and lower sales in select product categories.
Sales from the company's US healthcare unit jumped to $2.17 billion in the first fiscal quarter, up more than 12% from the same period a year ago. Analysts had expected sales of $2.09 billion, according to estimates compiled by StreetAccount.
That partly reflects growth in primary care provider VillageMD and specialty pharmacy company Shields Health Solutions. Specialty pharmacies are designed to deliver medications with unique handling, storage and distribution requirements, often for patients with complex conditions.
Walgreens' international unit, which operates more than 3,000 retail stores overseas, booked $6.43 billion in sales in the first fiscal quarter. That's an increase of 10.2% from last year.
Analysts had expected revenue of $5.85 billion for the period, according to StreetAccount.
The company said sales from its UK-based drug chain, Boots, were up 4.5%.